Earnings ·
CV Sciences reported second quarter 2026 financial results for the period ended June 30, 2026
CVSICV Sciences, Inc.
CV Sciences reported second quarter 2026 financial results for the period ended June 30, 2026. Revenue decreased 17.5% to $3.0 million from $3.6 million in the prior year quarter, driven by lower sales volume and restrictive regulations. The company recognized a gross margin of 48.6% and reduced operating expenses by 11.3% to $1.7 million. Adjusted EBITDA was a loss of $0.1 million compared to positive adjusted EBITDA in the prior year period. Cash balance stood at $0.3 million at quarter end. The company also launched PlusHLTH.com and expanded its +PlusHLTH™ portfolio while noting regulatory delays for hemp-derived products. CV Sciences operates in the consumer wellness industry, specializing in hemp extracts and natural ingredients.